Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat
Key Clinical Message Recently, hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitors have been used for renal anemia, but side effects have also been reported. We report on the association of central hypothyroidism and cholesterol with roxadustat. Based on this case and previous reports, w...
Saved in:
| Main Authors: | Serina Kita, Hiroshi Okuyama, Takaya Kondo, Mizuki Hayashi, Shinichiro Nakao, Toshitaka Sawamura, Keiji Fujimoto, Atsushi Nakagawa, Hitoshi Yokoyama, Kengo Furuichi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.9400 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Influencing factors of clinical efficacy of roxadustat among hemodialysis patients
by: Wenhui Wu, et al.
Published: (2024-12-01) -
The Efficacy and Safety of Roxadustat for Anemia in Hemodialysis Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials
by: Yunling Geng, et al.
Published: (2024-11-01) -
Nanoscale Systems for Local Activation of Hypoxia-Inducible Factor-1 Alpha: A New Approach in Diabetic Wound Management
by: Saber S, et al.
Published: (2024-12-01) -
Endothelial Cell‐Specific Prolyl Hydroxylase‐2 Deficiency Augments Angiotensin II–Induced Arterial Stiffness and Cardiac Pericyte Recruitment in Mice
by: Bo Liu, et al.
Published: (2024-08-01) -
Mitophagy mediated by HIF-1α/FUNDC1 signaling in tubular cells protects against renal ischemia/reperfusion injury
by: Wenjun Zhang, et al.
Published: (2024-12-01)